Acute lymphocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, p49/p100 as well as p105 maps to regions associated with certain types of acute lymphoblastic leukemia.
|
1612589 |
1992 |
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Interestingly, p49/p100 as well as p105 maps to regions associated with certain types of acute lymphoblastic leukemia.
|
1612589 |
1992 |
Lymphoma
|
0.020 |
Biomarker
|
group |
BEFREE |
Although p105 content tended to be higher in HAL than in an AIDS-related complex (ARC)-associated hyperplastic lymph node control, no statistically significant associations were found between p105 content and proliferative activity or the number of mitoses per 10 high-power fields.
|
1677032 |
1991 |
AIDS related complex
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although p105 content tended to be higher in HAL than in an AIDS-related complex (ARC)-associated hyperplastic lymph node control, no statistically significant associations were found between p105 content and proliferative activity or the number of mitoses per 10 high-power fields.
|
1677032 |
1991 |
Hyperplastic lymph node
|
0.010 |
Biomarker
|
disease |
BEFREE |
Although p105 content tended to be higher in HAL than in an AIDS-related complex (ARC)-associated hyperplastic lymph node control, no statistically significant associations were found between p105 content and proliferative activity or the number of mitoses per 10 high-power fields.
|
1677032 |
1991 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 was done on cancer cell suspensions from 114 advanced gastric cancers and correlated with clinical behavior.
|
1913456 |
1991 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 was done on cancer cell suspensions from 114 advanced gastric cancers and correlated with clinical behavior.
|
1913456 |
1991 |
Malignant neoplasm of stomach
|
0.030 |
Biomarker
|
disease |
BEFREE |
Flow cytometric quantitation of the proliferation-associated nuclear antigen p105 was done on cancer cell suspensions from 114 advanced gastric cancers and correlated with clinical behavior.
|
1913456 |
1991 |
Carcinoma
|
0.050 |
Biomarker
|
group |
BEFREE |
The expression of proliferation-associated nuclear antigen p105 of gastric carcinomas was studied by multiparameter flow cytometric and immunohistochemical technique.
|
2015552 |
1991 |
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The expression of proliferative-associated nuclear antigen p105 in gastric carcinoma.
|
2015552 |
1991 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Nuclear antigen quantitation of diploid tumors showed a wide range of p105 expression in G0G1 cells, suggesting that, within each tumor, the cells are heterogeneous with respect to proliferative activity.
|
2377285 |
1990 |
Glioma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Aneuploid nuclei of glial tumors showed enhanced expression of p105 relative to diploid cells of the same specimen.
|
2377285 |
1990 |
Lymphoma
|
0.020 |
Biomarker
|
group |
BEFREE |
We have performed two-color flow cytometric quantitation of nuclear antigen p105 and DNA content in nuclear suspensions from 80 paraffin-embedded lymphomas.
|
2569301 |
1989 |
Hodgkin Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Flow cytometric measurements of proliferation-associated nuclear antigen p105 and DNA content in non-Hodgkin's lymphomas.
|
2569301 |
1989 |
High Grade Lymphoma (neoplasm)
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
High-grade lymphomas with diploid DNA histograms tended to express high levels of p105 in all phases of the cell cycle.
|
2569301 |
1989 |
Myomatous neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Simultaneous flow cytometric quantitation of DNA content and the proliferation-associated nuclear antigen p105 was performed on 41 gastrointestinal smooth muscle neoplasms and the results were correlated with histologic features.
|
3202248 |
1988 |
Myeloid Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The results of different investigators show that lack of p105 expression is relatively common in human myeloid leukemias, especially in monocytic leukemias.
|
7773151 |
1995 |
Human immunodeficiency virus (HIV) II infection category B1
|
0.010 |
Biomarker
|
disease |
BEFREE |
Regulation of I kappa B alpha and p105 in monocytes and macrophages persistently infected with human immunodeficiency virus.
|
7853483 |
1995 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The objectives of this Radiation Therapy Oncology Group (RTOG) protocol (91-08) were: (1) to correlate tumor proliferative potential estimated using the p105 assay and deoxyribonucleic acid (DNA) analysis with treatment outcome in patients irradiated for advanced squamous cell carcinoma of the head and neck; and (2) to evaluate the potential of p105 labeling indices as a predictive assay.
|
7913703 |
1994 |
Squamous cell carcinoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
These results suggest that flow cytometric quantitation of the proliferation-associated nuclear antigen p105 and DNA content of pretreatment tumor biopsies may be a potentially useful predictive assay in patients irradiated for advanced squamous cell carcinomas of the head and neck.
|
7913703 |
1994 |
Squamous cell carcinoma of the head and neck
|
0.010 |
Biomarker
|
disease |
BEFREE |
The objectives of this Radiation Therapy Oncology Group (RTOG) protocol (91-08) were: (1) to correlate tumor proliferative potential estimated using the p105 assay and deoxyribonucleic acid (DNA) analysis with treatment outcome in patients irradiated for advanced squamous cell carcinoma of the head and neck; and (2) to evaluate the potential of p105 labeling indices as a predictive assay.
|
7913703 |
1994 |
Lymphoma, Non-Hodgkin
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Twenty six high grade NHL samples (58%) showed no p105 expression.
|
8289506 |
1994 |
leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We conclude that abnormal expression of RB with absence of p105 or strongly reduced p105 levels occurs frequently in myelomonocytic and monoblastic leukaemias and that this may be correlated with a more malignant course of the disease.
|
8485048 |
1993 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Flow cytometry was also used to measure DNA Index and tumor S-phase fraction, in some cases using multiparameter analysis of isolated nuclei to determine DNA content and the level of the proliferation-associated antigen, p105.
|
8529468 |
1995 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Flow cytometric study of the proliferation-associated nuclear antigen p105 was done on cancer cell suspensions from 75 patients with renal cell carcinomas.
|
8756377 |
1996 |